- Paula Brown Stafford joins Allucent in a planned
leadership transition, bringing 35+ years of life science
experience, including with Quintiles and Novan, Inc., to guide
company's next phase of growth
- Mark A. Goldberg, M.D., who spearheaded Allucent's
transformation to a global CRO serving small and mid-sized
biopharmaceutical companies, will continue to serve as
chairman
CARY,
N.C., July 23, 2024 /PRNewswire/ --
Allucent today announced that it has appointed industry
veteran Paula Brown Stafford
as chief executive officer to advance the next phase of its
expansion. Ms. Stafford succeeds Mark A.
Goldberg, M.D., in a planned transition following his
leadership in building Allucent into a global clinical research
organization (CRO) uniquely positioned to serve small and mid-sized
biopharmaceutical businesses.
Allucent names Paula Brown Stafford as CEO to lead next phase
of expansion
Ms. Stafford brings to Allucent more than 35 years of industry
experience. At Quintiles (now IQVIA), she played a key role in
growing its CRO services. As president of the global life science
provider's largest business unit, she led 22,000 employees across
60 countries in delivering Phase I-IV clinical research services.
Ms. Stafford also was president, CEO and chairman of Novan, Inc., a
clinical development-stage biotechnology company.
Dr. Goldberg, who will continue to serve as chairman of
Allucent's board of directors, stated: "Paula is known for her
dynamic leadership and unwavering commitment to helping deliver
needed therapies to patients. Having held key positions at both a
biotech business and leading CRO, Paula brings a unique perspective
and expertise in drug development that will greatly benefit our
clients and team. Her proven track record in creating value and
driving innovation, combined with her passion for operational
excellence, will be instrumental in advancing Allucent's continued
success and growth."
Ms. Stafford will guide Allucent's continued expansion following
Dr. Goldberg's leadership in building the company into a global
provider of drug development solutions addressing the specialized
needs of small and mid-sized biotech businesses. Over the past five
years, the company has bolstered its portfolio of development
services, deepened its clinical capabilities and extended its
global reach to more than 60 countries.
Paula Brown Stafford, newly
appointed CEO of Allucent, said, "Mark has built Allucent into a
leading full-service CRO, addressing a crucial market gap for
smaller biotech companies at a time when innovative medicines and
efficient clinical success are more critical than ever. I am
honored to take on the role of CEO to further this vital mission.
With three decades of CRO experience and seven years leading a
small biopharmaceutical company, I am proud of my contributions to
the industry's growth and am well-versed in the needs of smaller
companies in today's drug development landscape. I look forward to
leveraging this expertise to tackle our clients' toughest
challenges and expedite the delivery of novel therapies to patients
in need."
Dr. Goldberg added, "Having led Allucent during this
formative time has been a privilege. We've established ourselves as
a world-class CRO tailored to the unique needs of small and
mid-sized biotechs. Our team is incredibly talented, and Paula is
the ideal choice to take Allucent to the next level. As Chairman of
the Board, I am excited to continue to support Allucent's journey
and am confident in our bright future with Paula at the helm."
Ms. Stafford's contributions to the life science industry and
North Carolina community have been
recognized by multiple organizations. The Triangle Business
Journal presented her with its Lifetime Achievement Award for
Women in Business (2022) and Fierce Biotech named her one of
the 10 top women in biotech (2012). The University of North Carolina at Chapel Hill, where
Ms. Stafford serves as an adjunct professor for the Gillings
School of Global Public Health, presented her with its
Distinguished Alumna award (2016).
About Allucent
Allucent is on a mission to help
bring new therapies to light by solving the distinct challenges of
its biopharma and government clients. Allucent is a global provider
of comprehensive drug development solutions, including consulting,
clinical operations, biometrics, and clinical pharmacology across
various therapeutic areas. With more than 30 years of experience in
over 60 countries, Allucent's individualized partnership
approach provides experience-driven insights and expertise to
assist its clients in successfully navigating the complexities of
delivering novel treatments to patients.
Visit Allucent.com for more information.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/allucent-names-paula-brown-stafford-as-ceo-302203553.html
SOURCE Allucent